Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells
about
CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19Genetically modified T cells for the treatment of malignant diseaseLinking form to function: Biophysical aspects of artificial antigen presenting cell designIndividual Motile CD4(+) T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells.Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectivesCD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic LeukaemiaManufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapiesRedirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ TumorsAssociation of new deletion/duplication region at chromosome 1p21 with intellectual disability, severe speech deficit and autism spectrum disorder-like behavior: an all-in approach to solving the DPYD enigmaBioengineering T cells to target carbohydrate to treat opportunistic fungal infection.Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral vectors.The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptorsHuman cell-based artificial antigen-presenting cells for cancer immunotherapy.Activating and propagating polyclonal gamma delta T cells with broad specificity for malignanciesClinical applications of gamma delta T cells with multivalent immunity.Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.Dihydrofolate Reductase and Thymidylate Synthase Transgenes Resistant to Methotrexate Interact to Permit Novel Transgene Regulation.CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.Costimulation with anti-cluster of differentiation 3 and anti-cluster of differentiation 28 reduces the activity of mucin 1-stimulated human mononuclear cells.Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System.Immunotherapy in glioblastoma: emerging options in precision medicinePhase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cellsImmunotherapy for opportunistic infections: Current status and future perspectives.Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.Global Manufacturing of CAR T Cell Therapy.Engineering of PEDF-Expressing Primary Pigment Epithelial Cells by the SB Transposon System Delivered by pFAR4 Plasmids.Antibody-modified T cells: CARs take the front seat for hematologic malignancies.Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.The use of endogenous T cells for adoptive transfer.Biomedical techniques in translational studies: The journey so far.Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective.Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.Human artificial chromosomes for Duchenne muscular dystrophy and beyond: challenges and hopes.Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells.Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors.Synthetic biology in cell-based cancer immunotherapy.Bioengineering solutions for manufacturing challenges in CAR T cells.
P2860
Q26783433-BF15EDA1-E499-4536-AD3E-5BF0600DC1C2Q26849476-DA782D6F-2B7A-49EA-B212-7DD486C922CEQ26860657-EAACD055-EE91-4C93-812E-411E765E2D7CQ27002652-215C1CA3-2ED1-4986-9912-D77A1066EE38Q27345402-7F0EF177-1A13-43C2-976E-AA53B1882B24Q28074002-6CC2CAD2-4F11-491B-A991-630B74674031Q28081600-DE76F812-70EF-4CB9-A5F9-BDA79E114D21Q28085769-E2ACC08C-CC4D-41AB-A6F8-C1A8885F8BB4Q28553650-9057459C-3918-4ACF-ACC9-8FB3D56D4632Q28596636-95AD77FF-E2E9-496E-A0CB-9BA6C89C3CF8Q30585324-B7878B71-C2B3-468C-A4BA-E9CCB45B0932Q34082215-F0EB1763-D0B8-4C6E-8D19-C380A15A7257Q34309388-82372729-CFAD-472E-AE3C-3750CA6C6594Q34391263-0E14ECD8-7378-4556-AC28-3D8943679CFEQ34517192-9B2E20B0-D9BC-46BB-BEA4-A45EE739C981Q34677859-2DC6502E-73B3-4FC5-B6B6-A424252E36A8Q35648352-695C1CE7-D9C6-4075-A512-EBD2F08D02ACQ35877585-A1AF6FCD-9C7F-4A8D-B889-5B72FADCAA52Q36281621-EC7FE233-162C-4B35-9DA9-05A038287F4CQ36512076-89416AC0-A16B-4CCA-B950-1BA0353BD6FEQ36519394-8E9DA32D-3C3F-4AEB-8CF7-F2FA427A250DQ37043492-F3987525-E94A-4961-9793-80F3980C18F6Q37050960-D9C999D0-F7C1-435F-B9CB-7676EDA039B7Q37217432-CA207E66-BB51-4A44-8885-F6A3938A7D23Q37474007-11448C7D-7582-4C87-B2FB-ECB6ACF83343Q37509216-EF625293-4F03-4AD4-BD93-575620EB3169Q37588329-1BF5ED82-E952-4717-97F3-6C73E2551599Q37717884-4EB4E2A7-4C39-4B55-9F19-B7B8685284F0Q37718218-CB6E4765-9CCC-4C87-8294-EBF3EA4074C1Q37723469-55AC7A15-D2F0-4318-A334-49ECC6E1CA8DQ38155343-DA05A001-5499-4E34-884F-2DFD2A15E709Q38170503-11E9A397-01E4-4C4A-9665-21A3D6F8A786Q38208852-91175BC9-0B04-4D72-ACC7-E039EBAC1F86Q38285256-C6AD3D58-0983-4E4E-83BE-460BE6CF7BB7Q38319552-6F5B1CE9-2821-4036-9C79-6B2B91315B2DQ38321965-D1F01A34-0C18-4040-9BC2-D24056E70ACCQ38353123-D6FF2476-54D7-4458-8FBF-198169F7666DQ38525034-44D16419-8DA2-4876-9927-A962074B9024Q38531361-2FD2439A-9DF3-4F1F-884E-9D926684A25AQ38637370-F8C18627-E653-465D-B45D-43BE60B90992
P2860
Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Manufacture of clinical-grade ...... icial antigen presenting cells
@ast
Manufacture of clinical-grade ...... icial antigen presenting cells
@en
Manufacture of clinical-grade ...... icial antigen presenting cells
@nl
type
label
Manufacture of clinical-grade ...... icial antigen presenting cells
@ast
Manufacture of clinical-grade ...... icial antigen presenting cells
@en
Manufacture of clinical-grade ...... icial antigen presenting cells
@nl
prefLabel
Manufacture of clinical-grade ...... icial antigen presenting cells
@ast
Manufacture of clinical-grade ...... icial antigen presenting cells
@en
Manufacture of clinical-grade ...... icial antigen presenting cells
@nl
P2093
P2860
P1433
P1476
Manufacture of clinical-grade ...... icial antigen presenting cells
@en
P2093
Bipulendu Jena
Harjeet Singh
Helen Huls
Laurence J N Cooper
Ling Zhang
Margaret J Dawson
Matthew J Figliola
Pallavi Manuri
Partow Kebriaei
P2860
P304
P356
10.1371/JOURNAL.PONE.0064138
P407
P577
2013-05-31T00:00:00Z